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It is now nearly 30 years since cyclical combination chemotherapy
with MO(orV)PP (mustine (mechlorethamine), vincristine
(Oncovin) or vinblastine (Velbe), procarbazine and prednisolone)
revolutionized the management of advanced Hodgkin’s disease
(Devita et al, 1970; Nicholson et al, 1970). Long-term survival was
observed in approximately half of the patients treated with these
regimens (Longo et al, 1986; Linch and Vaughan Hudson, 1988). 
The Milan group developed an Adriamycin containing regimen,
ABVD (Adriamycin (doxorubicin), bleomycin, vinblastine, dacar-
bazine), (Santoro et al, 1982) and alternated this with MOPP, in
accordance with the Goldie-Coldman hypothesis (Goldie et al,
1982). Their trial comparing MOPP/ABVD with MOPP alone
showed the alternating approach to be superior. However, other
studies comparing single with alternating regimens produced
conflicting results (Gans et al, 1982; Vinciguerra et al, 1986;
Longo et al, 1991; Canellos et al, 1992). 
Also the Cancer and Leukaemia Group B (CALGB) trial (where
ABVD and MOPP/ABVD were equally efficacious and both
better than MOPP) implied that any improvements in treatment
results may have been due simply to the use of a more active doxo-
rubicin-containing regimen, rather than a consequence of alter-
nating combinations (Canellos et al, 1992). The importance of this
question was reinforced by increasing evidence of permanent
infertility in males and second malignancies in patients treated
with alkylating agents and procarbazine. 
Other groups have substituted chlorambucil for mustine in an
attempt to increase patient acceptability, and hence compliance, by
reducing the toxicity of chemotherapy whilst maintaining efficacy.
The resulting ChlVPP regimen appeared to fulfil this aim (Selby 
et al, 1980). The British National Lymphoma Investigation (BNLI)
confirmed this in a randomized study of 299 patients where LOPP
(L for Leukeran (chlorambucil)) was compared with MOPP
(Hancock et al, 1991). The trend towards enhanced acceptability
continued with a study by the Central Lymphoma Group (CLG), in
which the ABVD component in alternating therapy was modified
by replacing dacarbazine with etoposide, adding prednisolone,
and switching vinca alkaloids to form PABIOE (prednisolone,
Adriamycin (doxorubicin), bleomycin, Oncovin (vincristine),
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Summary The purpose of this randomized trial was to compare the efficacy of 6 cycles of prednisolone, Adriamycin (doxorubicin), bleomycin,
vincristine (Oncovin) and etoposide (PABlOE) with 3 cycles of PABIOE that alternate with 3 cycles of chlorambucil, vinblastine, procarbazine
and prednisone (ChlVPP) in patients with advanced Hodgkin’s disease. Between October 1992 and April 1996, 679 patients were entered
onto the study. 41 of these did not match the protocol requirements on review and were excluded from further analysis, most of these being
reclassified as NHL on histological review. Of the remaining 638 patients, 319 were allocated to receive PABIOE and 319 were allocated to
receive ChlVPP/PABlOE. The complete remission (CR) rates were 78% and 64%, for ChlVPP/PABlOE and PABIOE respectively after initial
chemotherapy (P < 0.0001). 124 patients were re-evaluated subsequently following radiotherapy to residual masses. The CR rates changed
from 78% to 88% for ChlVPP/PABlOE and from 64% to 77% for PABlOE when re-evaluated in this manner (treatment difference still
significant, P = 0.0002). The treatment associated mortality in the PABlOE arm was 2.2% (7 deaths), while there were no such deaths in the
ChlVPP/PABlOE arm (P = 0.015). The failure-free survival was significantly greater in the ChlVPP/PABlOE arm (P < 0.0001) as was the
overall survival (P = 0.01). The failure-free and overall survival rates at 3 years were 77% and 91% in the ChlVPP/PABlOE arm, compared
with 58% and 85% in the PABIOE arm, respectively. These results indicate that ChlVPP alternating with PABIOE is superior to PABIOE alone
as initial treatment for advanced Hodgkin’s disease. © 2001 Cancer Research Campaign http://www.bjcancer.com
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1994). In 216 patients with advanced Hodgkin’s disease treated
with this regimen the 5-year survival was 78%. At the same time
the BNLI showed that LOPP alternating with EVAP (etoposide,
vinblastine (Velbe), Adriamycin (doxorubicin), prednisolone) was
superior to LOPP alone in a randomized trial including 594
patients (Hancock et al, 1992). 
In view of the similarity of PABIOE to ABVD and the favour-
able results for ABVD in the randomized (albeit small) CALGB
(Canellos et al, 1992) the BNLI and CLG combined to compare
the effective ChlVPP/PABIOE regimen with PABIOE alone in a
randomized, multicentre trial in advanced HD. 
PATIENTS AND METHODS 
Patients 
The criteria for inclusion were as follows: stage I or II disease with
either bulky disease or ‘B’ symptoms or stage III or IV disease;
age 15 years to 69 years; opportunity for adequate long-term
follow-up must have been anticipated; freedom from any other
known serious disease that might limit severely the patient’s life
expectancy; no previous chemotherapy and/or radiotherapy (RT)
except as an emergency measure for obstructive symptoms;
surgical staging was not required, but all patients were required to
have either lymphangiography or computed tomographic (CT)
scanning of the abdomen; histopathologic diagnosis confirmed by
the BNLI/CLG histopathology panel; and informed consent
obtained. Ethics committee approval for the study was obtained at
all anticipating centres. 
Patients were randomized to receive either PABIOE or ChlVPP
alternating with PABIOE. Randomization was performed by a
telephone call to one of two central offices using cards within
sealed envelopes without stratification. Staging was performed
according to the Ann Arbor criteria (Carbone et al, 1971) and
histologic grading according to previously published BNLI criteria
(Bennett et al, 1989). 
Treatment 
Chemotherapy regimen doses and scheduling are listed in Table 1.
Patients were completely reassessed after 3 cycles of chemo-
therapy. If the patient was in clinical CR at this time, 3 additional
cycles of chemotherapy were scheduled (i.e. a total of 6 cycles). If
after 3 cycles the assessment showed the patient to be progres-
sively improving, then the treatment was continued (provided
that progressive improvement persisted) until a clinical CR was
attained, after which 2 more cycles of chemotherapy were sched-
uled (i.e. a total of 8 cycles for a patient in clinical CR after the
sixth cycle). The maximum number of 8 cycles was stipulated. If
there was progressive disease, no progressive improvement or
disease relapse then treatment was changed. Salvage therapy was
as the local clinician’s discretion. 
Patients who had a CR with chemotherapy were eligible for
further randomization to radiotherapy (35 Gy in 20 fractions in 
4 weeks) to areas of bulk disease (>5 cm) or no radiotherapy.
Involved field radiotherapy was used such that the disease was
encompassed in one treatment volume. The use of extended field
radiotherapy to cover sites which were either not involved with
HD initially or contained non-bulky HD was not recommended to
avoid excessive bone marrow irradiation. The routine use of
involved field radiotherapy after CR with chemotherapy was also
not recommended. Patients who had a PR with chemotherapy
could receive involved field radiotherapy (35–40 Gy in 20 frac-
tions in 4 weeks) to residual masses. 
Of the 642 patients randomized to either of the chemotherapy
regimens, 208 patients (32%) received radiotherapy after comple-
tion of chemotherapy (ChlVPP/PABIOE, 107 patients, PABIOE,
101 patients) (Table 2). 
61 patients in CR after chemotherapy were randomized between
radiotherapy (32 patients) and no radiotherapy (29 patients). 3
patients randomized to radiotherapy did not receive it (refusal,
2 patients; disease progression, 1 patient). Thus 179 patients
received radiotherapy after chemotherapy other than the 29
patients in the radiotherapy trial. Of these 179 patients, 54 patients
were in CR after chemotherapy and 124 patients were in PR (119
patients) or NR (5 patients). In one patient the remission status was
unknown. 
Clinical response was determined by repeating initially ab-
normal investigations. Investigation of persisting equivocal abnor-
malities was at the discretion of the  clinician; CRu (uncertain)
was not recorded. 
Statistical methods 
The main endpoint of the study was survival. Secondary endpoints
were failure-free survival and achievement of CR. The trial was
set up with an intention to recruit 700 patients. This would enable
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Table 1 Regimen doses
PA(BI)OE regimen
Prednisolone 40 mg/m2 (maximum 60 mg) p.o. daily for 10 days 
Adriamycin (doxorubicin) 40 mg/m2 iv day 1 
Bleomycin 10 units/m2 days 1 and 8 for first 4 cycles only
Vincristine 1.4 mg/m2 (maximum 2 mg) i.v. Days 1 and 8 
Etoposide 200 mg/m2 p.o. daily for 3 daysa
Cycle repeated every 21 days maximum 8 cycles 
ChlVPP/PABIOE regimen 
Chlorambucil 6 mg/m2 (maximum 10 mg) p.o. daily days 1–14 
Vinblastine 6 mg/m2 (maximum 10 mg) i.v. days 1 and 8 
Procarbazine 100 mg/m2 (maximum 200 mg) p.o. daily days 1–14 
Prednisolone 40 mg/m2 (maximum 60 mg) p.o. daily days 1–14 
The alternation of ChlVPP/PABIOE consists of initial treatment with a cycle of ChIVPP for 2 weeks followed by a 2 week gap with no chemotherapy. At the
beginning of the 5th week a cycle of PABIOE is given and lasts for 10 days. There is an 11 day gap without chemotherapy and then the next cycle of ChlVPP
begins (maximum 8 cycles 4 ChlVPP, 4PABIOE). 
aIf nadir (day 10–14) WBC <1.0 ´ 109 l–1 decrease etoposide to 2 days. If nadir WBC > 1.5 ´ 109 l–1 increase etoposide to 4 days. the detection of a 10% difference in survival at 5 years with a 5%
chance of a false positive result and a 10% chance of a false nega-
tive result. Survival was calculated as the time from randomization
to death, or to the date of last follow-up if the patient was still
alive. The data included follow-up until June 1998. CR was
defined as complete disappearance of all disease for a minimum of
1 month after the completion of therapy. PR was defined as the
disappearance of at least 50% of known disease. CR rates were
compared in the 2 arms of the trial by use of Fisher’s Exact Test
where possible and otherwise by a chi-squared (c2) test with Yates’
correction. 
Survival curves were calculated by the method of Kaplan and
Meier (1958) and statistical comparison of curves was performed
by the log-rank test as described by Peto et al (1977). The hazard
ratio, with associated confidence limits (Altman, 1991), was used
to quantify the increased risk associated with one treatment
compared to the other. This assumes proportional hazards
throughout the time period of the study, and enables a single
measure to be used to quantify any treatment difference. Failure-
free survival was recorded as the time to progression for complete
and partial responders, and time to treatment failure for non-
responders. 2 patients (one in each arm) who received high-dose
chemotherapy (HDC) in partial remission without having relapsed
were censored at the date of HDC when calculating failure-free
survival. This was done to avoid bias since this was an additional
non-protocol treatment. 
Factors affecting achievement of complete remission were
analysed using multivariate logistic regression methods. Cox’s
multivariate proportional hazards model (Cox, 1972) was used to
evaluate prognostic factors for failure-free and overall survival.
For these multivariate analyses some variables had a few missing
values. To enable inclusion of all the patients in the analyses these
missing values were estimated (imputed) by linear regression
methods using values from other available variables. The analyses
were also undertaken without the imputed values, to confirm the
results, which in all cases were nearly identical in magnitude. A
significance level of 0.05 was used for inclusion in all the multi-
variate models. 
Continuous factors such as age, albumin and WBC were
grouped categorically with different cut-off points and compared
with the results when analysed continuously, in order to determine
sensible prognostic groups as suggested by Wagstaff et al
(Wagstoff et al, 1988). Cut-offs used by others were considered
where possible. For instance, Dhaliwal et al (Dhaliwal et al, 1993)
analysed albumin in 3 subgroups, namely ³ 32, 33–39 and ≤ 40.
We combined adjacent equivalent groups, thus finding, in this case
for albumin, that very low albumin values (≤ 32) predicted for
poor response while higher values (³ 40) predicted for better
failure-free survival. 
RESULTS 
Patients 
A total of 679 patients were entered onto this trial between
October 1992 and April 1996. The trial was prematurely closed
when interm analysis of data available as of January 1996 showed
a significant difference between the arms of the study. Patients still
on study receiving PABIOE were converted to ChlVPP/PABIOE. 
Exclusions 
Of the 679 patients randomized 41 (6%) were excluded from anal-
ysis. Reasons for exclusion were: 21 incorrect histology on review,
4 too old, 6 previously treated, 1 previous cancer, 3 treatment
protocol violations and 6 converted to ChlVPP/PABIOE after trial
stopped. 
Patient and chemotherapy characteristics 
The 2 arms of the trial were balanced for all patient characteristics.
(Table 3). More patients on ChlVPP/PABIOE received 8 cycles of
treatment but this was not statistically significant (Table 4). 
Response (Table 5) 
Response was available in 313 of the 319 patients randomized to
receive PABIOE, and 200 of these (64%) achieved CR. Of the 319
randomized to receive ChlVPP/PABIOE 247/315 (78%) achieved
CR. The difference in complete response rate (78% vs 64%) was
significant ( c2 with Yates correction = 15.4, P < 0.0001). 124
patients were subsequently re-evaluated following radiotherapy to
residual masses (ChlVPP/PABIOE: 55 patients, PABIOE: 69
patients). The CR rates changed to 88% (278/315) for ChlVPP/-
PABIOE and to 77% (240/313) for PABIOE when re-evaluated in
this manner (treatment difference still significant, c2 with Yates
correction = 13.8, P = 0.0002). 72 patients were converted from
PR to CR with additional radiotherapy and one from NR to PR.
The duration of response of these 72 patients is very similar to that
of the complete responders after chemotherapy (data not shown). 
The logistic regression analysis (see Table 6) showed that treat-
ment with PABIOE (P < 0.0001, odds ratio 2.1), white blood count
(WBC) ³ 20 ´ 109 l–1 (P = 0.005), albumin ≤ 32 g l–1 (P = 0.01) and
being Nodular Sclerosis Grade II histology (P = 0.02) predicted
for a worse proportion achieving complete response. There was no
significant effect of age on complete response rate (P = 0.34). 
38 of 66 (58%) relapsers in the ChlVPP/PABIOE arm subse-
quently needed high-dose therapy (with autologous peripheral
blood stem cell or bone marrow transfusion) compared with
75/120 (63%) in the PABIOE arm (P = 0.53, Fisher’s Exact test).
So although twice as many patients in the PABIOE arm received
high-dose therapy (HDT) the proportions in the 2 arms were
similar. Follow-up after relapse is short in these patients to date so
the simple proportion of patients receiving HDT is an underesti-
mate of the eventual numbers likely to require it. Actuarially the
proportions of patients receiving HDT are approximately 80% in
both arms one year following relapse (data not shown).The
survival of those patients requiring salvage therapy after failure of
first line treatment was similar in both arms (data not shown). 
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Table 2 Number of patients receiving radiotherapy 
Response to  ChlVPP/PABIOE  PABIOE
chemotherapy No. receiving RT No. receiving RT
CR 52 31 
PR 52 67 
NR 2 3 
Unknown 1 0 
Total 107 101 Failure free survival (Figure 1) 
There was a significant difference in the failure-free survival
(FFS) between treatment groups (c2 = 25.6, P < 0.0001), with the
hazard of failure for ChlVPP/PABIOE being approximately half
that for PABIOE (50% ± 10%). At 3 years the FFS rates were 
77% and 58% for ChlVPP/PABIOE and PABIOE, respectively.
On multivariate analysis (see Table 7) the factors predicting 
for better FFS were treatment with ChlVPP/PABIOE (c2 = 29.4, 
P < 0.0001), stage (I + II better than III better than IV, c2 = 14.0, 
P = 0.0002), albumin ³40 (c2 = 6.7, P = 0.01), WBC < 20 
(c2 = 6.1, P = 0.01) and not having mixed cellularity histology ( c2
= 4.8, P = 0.03). The hazard for progressing on PABIOE compared
to ChlVPP/PABIOE was virtually unchanged (2.01 changing to
2.12) after allowance for the other significant factors (stage,
albumin and WBC). 
Overall survival (Figure 2) 
The median duration of follow-up was 2.7 years (range 3 months
to 5 1/2 years). There was a significant difference in overall
survival between the 2 regimens (c2 = 6.06, P = 0.01). The hazard
of death was increased by 43% ± 18% in the PABIOE arm
compared to the ChlVPP/PABIOE arm. The magnitude of this
effect is not dissimilar from that for failure-free survival (50% ±
10%, see Figure 1), although the P value is clearly much less
significant. This is because there are many more failures than
deaths in the trial so far. At 3 years the survival rates were 91%
and 85% for ChlVPP/PABIOE and PABIOE, respectively. Stage I
patients fared slightly worse than stage II patients (P = 0.04), prob-
ably because they had more bulky disease (however, only 51 (8%)
stage I patients were included). Using Cox’s proportional hazards
model analysis (see Table 7) the factors predicting for better
overall survival were age <50 years (c2 = 24.6, P < 0.0001), stage
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Table 3 Patient characteristics by treatment 
ChIVPP/PABIOE PABIOE 
Total number of patients randomized 337 342 
Number of ineligible patients 18 23 
Total used in analysis 319 (100%) 319 (100%) 
Age (years) 15–49 269 (84%) 268 (84%) 
³ 50 50 (16%) 51 (16%) 
Gender Male 191 (60%) 191 (60%) 
Female 128 (40%) 128 (40%) 
Stage I 19 (6%) 32 (10%) 
II 156 (49%) 136 (43%) 
III 76 (24%) 89 (28%) 
IV 67 (21%) 61 (19%) 
Not known 1 (1%) 1 (1%) 
Symptoms A 112 (35%) 114 (35%) 
B 203 (63%) 203 (64%) 
Not known 4 (1%) 2 (1%) 
Histology Mixed cellularity 49 (15%) 56 (18%) 
Lymphocyte depleted 3 (1%) 2 (1%) 
Nodular sclerosis (NS)I 139 (44%) 132 (41%) 
Nodular sclerosis (NS)II 119 (37%) 125 (39%) 
Not known 9 (3%) 4 (1%) 
Centre BNLI 218 (68%) 215 (67%) 
CLG 101 (32%) 104 (33%) 
WBC (x 109 l–1) <20 295 (93%) 292 (92%) 
³20 12 (4%) 15 (5%) 
Not known 12 (4%) 12 (4%) 
Albumin (g l–1) <40 153 (48%) 145 (45%) 
³40 143 (45%) 149 (47%) 
Not known 23 (7%) 25 (8%) 
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Figure 1 Failure-free survival by treatment 
Table 4 Number of cycles received 
Cycle ChIVPP/PABIOE PABIOE 
n % n % 
0 1 (0) 0 (0) 
1 6 (2) 6 (2) 
2 3 (1) 4 (1) 
3 3 (1) 8 (3) 
4 8 (3) 14 (4) 
5 4 (1) 9 (3) 
6 171 (55) 181 (58) 
7 13 (4) 21 (7) 
8 102 (33) 70 (22) 
This information was unavailable in 14 patients; 8 on the ChIVPP/PABIOE
arm and 6 on the PABIOE arm. (I + II better than III better than IV, c2 = 9.3, P = 0.002), WBC <20
(c2 = 5.5, P = 0.02) and absence of B symptoms (c2 = 6.5, 
P = 0.01). The significance of treatment remained unchanged 
(c2 = 6.8, P = 0.009) in the multivariate analysis, having adjusted
for the effects of these 4 factors. 
Duration of remission (Figure 3) 
There was a significant difference in remission duration by treat-
ment (c2 = 3.76, P = 0.05) with a 32% ± 17% reduction in the
hazard of relapse in the ChlVPP/PABIOE arm compared to the
PABIOE arm. The number of events was, however, small.
Toxicity (Table 8) 
There were 7 early deaths that were probably related to treatment
(septicaemia, with residual Hodgkin’s disease in all except 2) in
the PABIOE arm and no treatment-related deaths in the ChlVPP/-
PABIOE arm (P = 0.015, Fisher’s Exact Test). 
Information was collected for haematological toxicity, infec-
tions and neuropathy. The data presented is the worst WHO
toxicity score over the entire treatment period. Haematological
toxicity data was available for 507 patients; data on infection was
available in 500 patients and on neuropathy in 494 patients. 
It is apparent that Ch1VPP/PABIOE results in more haemato-
logic suppression (c2
1 (trend) = 32.15, P < 0.0001). Though the
incidence of infection was not different between the 2 treatments
(c2
1 (trend) = 0.96, P = 0.33), more neuropathy was seen in the
PABIOE arm (c2
1 (trend) = 6.5, P = 0.01). Other toxicities
(gastrointestinal, skin, phlebitis, alopecia, effects of steroids) were
not different between the 2 arms. 
Mortality (Table 9)
There have been 48 deaths in the PABIOE arm and 27 deaths in the
ChlVPP/PABIOE arm. Death in both groups was related mostly to
disseminated Hodgkin’s disease. A total of 4 patients died from
secondary malignancy (2 in each arm). 
DISCUSSION 
The ChlVPP/PABIOE regimen is a modification of MOPP/ABVD
with reduced subjective toxicity (substituting chlorambucil for
mechlorethamine, and etoposide for dacarbazine) (Cullen et al,
1994). There are also scheduling changes resulting in an increase
in anthracycline dose-intensity and a reduction in overall treatment
duration. The CR rate for ChlVPP/PABIOE (plus radiotherapy
where indicated) in the present randomized trial is 87% compared
with 85% in the phase II study. The overall survival at 3 years is
91% compared with 78% at 5 years in phase II. The efficacy of this
regimen has clearly been maintained in the transition from phase II
(in 216 patients) to phase III (in 319 patients). 
During this same period ABVD was shown to be superior to
MOPP and possibly equivalent to MOPP/ABVD, although with
only 115 to 123 patients per arm the CALGB trial was not powered
to detect small, perhaps clinically worthwhile differences
(Canellos et al, 1992). More recently ABVD was reported to be
equivalent to MOPP/ABV (Duggan et al, 1997). Consequently
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Figure 3 Duration of complete remission by treatment 
Table 5 Responses after chemotherapy alone and after additional radiotherapy 
ChIVPP/PABIOE +RT PABIOE +RT 
CR 247/315 (78%) 278/315 (88%) 200/313 (64%) 243/313 (78%) 
PR 58/315 (1/8%) 25/315 (8%) 93/313 (30%)  53/313 (17%) 
NR 10/315 (3%) 12/315 (4%) 20/313 (6%)  20/313 (6%) 
CR = Complete response; PR = Partial response; NR = Non response. 
Table 6 Multivariate logistic regression results for achievement of complete
remission 
Variable za P value ORb 95% CIc on
ORb
Treatment 4.0 <.0001 2.07 (1.45–2.98) 
WBC (<20 v ³20) 2.8 .005 3.20 (1.42–7.25) 
Albumin (≤32 v >32) 2.5 .01 1.90  (1.16–3.12) 
Histology (NSII v others) 2.3 .02 1.53  (1.06–2.20) 
a Standardized normal deviate; b Odds ratio; c Confidence interval.ABVD is widely used across the world, since the elimination of
mechlorethamine and procarbazine offers distinct long-term
toxicity advantages in preservation of fertility, and low incidence
of second malignancies (Canellos, 1996). 
The design of this trial comparing ChlVPP/PABIOE with non-
alternating PABIOE followed naturally in an attempt to demon-
strate similar equivalence of a less toxic regimen, including
preservation of fertility. In the event, PABIOE is clearly inferior in
efficacy, even after adjusting for other significant prognostic
factors (stage, albumin, and white cell count for failure-free
survival and stage, age, white cell count and B symptoms for
overall survival). Further similar attempts to minimize subjective
toxicity may be strictly limited. 
We are unable to explain the inferiority of the PABIOE regimen,
particularly in view of the favourable results for ABVD in the
CALGB trial (Canellos et al, 1992). However, progression-free
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Table 7 Cox’s proportional hazards regression model results 
1. Factors predicting for better failure-free survival 
Variable c2 P value HR* 95% CI on HRa
Treatment with ChIVPP/PABIOE 29.4 <.0001  2.15 (1.62–2.86) 
Stage (I+II>III>IV) 14.0 .0002  1.38 (1.17–1.64) 
Albumin ³ 40 6.7 .01 1.45 (1.09–1.92) 
WBC < 20 6.1 .01 2.00 (1.21–3.31) 
Histology other than MC 4.8 .03 1.56 (1.02–2.38) 
2. Factors predicting for better survival 
Variable c2 P value  HR* 95% CI on HRa
Age < 50 24.6 <.0001 3.62 (2.25–5.82) 
Stage (I+II>III>IV) 9.3 .002  1.54 (1.17–2.03) 
Treatment with ChIVPP/PABIOE 6.8 .009 1.85  (1.15–2.97) 
Absence of B symptoms 6.5 .01 2.05 (1.14–3.70) 
WBC < 20 5.5 .02 2.52 (1.27–5.20) 
a Hazard ratio. The following additional factors were included in these analyses and found not to be significant:
gender, histology, bone marrow involvement, haemoglobin, ESR, centre. 
Table 8 WHO toxicity grade by treatment 
WHO toxicity grade 
Toxicity Treatment 0 (%) 1 (%) 2 (%)  3 (%) 4 (%) 
Haematological ChIVPP/PABIOE 53 (21) 26 (10) 53 (21) 47 (19) 72 (29) 
PABIOE 91 (36) 44 (18) 49 (20) 38 (15) 28 (11) 
Infections ChIVPP/PABIOE 117 (48) 44 (18)  44 (18) 29 (12) 10 (4) 
PABIOE 123 (49) 54 (22) 41 (16)  25 (10) 8 (3) 
Neuropathy ChIVPP/PABIOE 129 (55) 84 (36)  17 (7) 5 (2) 1 (0) 
PABlOE 119 (47) 83 (33) 40 (16)  9 (4) 1 (0) 
Table 9 Causes of death 
Deaths(number) 
Cause ChIVPP/PABIOE PABIOE 
Hodgkin’s disease (HD) 21 29 
Treatment related – HD present 0 5 
Treatment related – without HD 0 2 
Treatment related – following subsequent high dose therapy after relapse 0 3 
Secondary leukaemia that caused death 2 0 
Secondary solid cancer that caused death 0 2 
Cardiac related 12  
Suicide (with HD present) 1 0 
Intercurrent disease – other cause 0 2 
Unspecified 23  
Total 27 48 and overall survival for PABIOE is similar to that found for LOPP
– the 4 drug regimen employed in the preceeding BNLI studies
(Hancock et al, 1992) (updated but unpublished data). 
The role of radiotherapy in advanced HD is still debated. Partial
remission may be converted to CR, as demonstrated in our study,
but in other situations (including previous bulk disease with
complete remission after full-course chemotherapy) overall
survival does not seem to be prolonged (Loeffler et al, 1998). 
The results with ChlVPP/PABIOE are similar to those reported
in multi-centre randomized trials incorporating doxorubicin-
containing regimens. These include alternating schedules i.e.
MOPP/ABVD (Bonadanna et al, 1986) LOPP/EVAP (Hancock 
et al, 1992), or ‘hybrid’ schedules i.e. ChlVPP/EVA (Radford et al,
1995), MOPP/ABV (Glick et al, 1998) which, in turn, produce
superior FFS to MOPP, LOPP, MVPP and sequential
MOPP/ABVD respectively. The devices of alternating different
combinations or ‘hybridizing’ active regimens may not, in them-
selves, be as important as the inclusion of enough of the most
effective drugs, in adequate dosage, in close enough time prox-
imity. The most recent device is dose-intensification with growth
factor support in regimens like Stanford V (Bartlett et al, 1995)
and escalated BEACOPP (Diehl et al, 1997). It remains to be seen
whether these are superior to the best non-intensified multi-drug
regimens listed above. If so, they may represent over-treatment for
many patients with advanced HD. ChlVPP/PABIOE is unique
among the very effective regimens tested in a multicentre context
in over 500 patients, in having no acute treatment-related
mortality. 
Finally, in those cases not requiring more intensive therapy
(which may be the majority), we need to know whether ABVD is
as good as the multi-drug regimens. To resolve this the UK
Lymphoma Group is now well advanced in a major randomized
comparison of ABVD with alternating ChlVPP/PABIOE or hybrid
ChlVPP/EVA with individual physicians selecting their preferred
multidrug regimen. The target accrual of 800 patients will be
achieved by late 2001. 
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